Latest Breaking News On - Family professorship - Page 4 : vimarsana.com

Published: Apr 23, 2021 Vaccine candidate demonstrates high efficacy at 77% in a study of children aged 5-17 months conducted in Africa Novavax Matrix-M™ adjuvant used in combination with University of Oxford malaria vaccine candidate, R21, and developed in collaboration with Serum Institute of India Phase 3 clinical trial to evaluate safety and efficacy begun in 4,800 participants aged 5-36 months GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax Matrix-M™ adjuvant and is licensed to Serum Institute of India (SII). Published online in

Burkina fasoUnited kingdomRegion du centre ouestUppsala lanLaura keenanCyrus poonawallaLakshmi mittalErika schultzGregorym glennJennifer porcelliAdrian hillSerum institute of india pvt ltdPrnewswire novavax incJenner institute at oxford universitySerum instituteSerum institute of india